Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia

The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for Enterobacterales in 2019, based on pharmacokinetic/pharmacodynamic analyses. However, clinical evidence supporting these breakpoint revisions is limited. A retrospective study was conducted at 3 ho...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Huang, Ho-Yin, Wang, Chu-Feng, Lu, Po-Liang, Tseng, Sung-Pin, Wang, Ya-Ling, Chen, Tun-Chieh, Chang, Ko, Tu, Hung-Pin, Lin, Shang-Yi
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2021
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315969/
https://ncbi.nlm.nih.gov/pubmed/33782006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00074-21
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados